Monitoring Src status after dasatinib treatment in HER2+ breast cancer with ⁸⁹Zr-trastuzumab PET imaging.

ABSTRACT:

Background

De novo or acquired resistance in breast cancer leads to treatment failures and disease progression. In human epidermal growth factor receptor 2 (HER2)-positive (HER2+) breast cancer, Src, a non-receptor tyrosine kinase, is identified as a major mechanism of trastuzumab resistance, with its activation stabilizing aberrant HER2 signaling, thus making it an attractive target for inhibition. Here, we explored the causal relationship between Src and HER2 by examining the potential of ⁸⁹Zr-trastuzumab as a surrogate imaging marker of Src activity upon inhibition with dasatinib in HER2+ breast cancer.

Methods

HER2+ primary breast cancer cell lines BT-474 and trastuzumab-resistant JIMT-1 were treated with dasatinib and assessed for expression and localization

SUBMITTER: McKnight BN 

PROVIDER: S-EPMC6203283 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature